EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria

Takashi Niizeki, Seiichi Mawatari iD, Michihiko Shibata, Ryu Sasaki iD, Shinji Itoh iD, Satoshi Shakado, Rie Sugimoto iD, Yusuke Morita, Takuya Kuwashiro, Mizuki Endo, Masao Iwao, Yasuhide Motoyoshi und 10 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.17024 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Takashi Niizeki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Quinolines. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria.

Methods

We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy ( n = 42) or Atez/Bev ( n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed.

Results

After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS.

Conclusion

LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticQuinolinesBevacizumabPhenylurea CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedTreatment OutcomeNeoplasm StagingPropensity ScoreCombined Modality TherapyRetrospective StudiesProgression-Free Survival

Stichwörter der Autor:innen

atezolizumab plus bevacizumabhepatocellular carcinomalenvatinibtransarterial chemoembolization

Substanzen

lenvatinibQuinolinesBevacizumabPhenylurea CompoundsAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
  • Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

ORCID-Profile: Seiichi Mawatari, Ryu Sasaki, Shinji Itoh, Rie Sugimoto, Masahito Nakano, Shigeo Shimose, Hirokazu Takahashi, Fumihito Hirai, Hisamitsu Miyaaki, Takumi Kawaguchi

Zitieren

APA

Niizeki, T., Mawatari, S., Shibata, M., Sasaki, R., Itoh, S., Shakado, S., Sugimoto, R., Morita, Y., Kuwashiro, T., Endo, M., Iwao, M., Motoyoshi, Y., Nakano, M., Shimose, S., Takahashi, H., Yatsuhashi, H., Hirai, F., Yoshizumi, T., Miyaaki, H., …, & Harada, M. (2025). Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.17024

Vancouver

Niizeki T, Mawatari S, Shibata M, Sasaki R, Itoh S, Shakado S, et al. Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.17024

BibTeX
@article{Niizeki2025,
  author = {Niizeki, Takashi and Mawatari, Seiichi and Shibata, Michihiko and Sasaki, Ryu and Itoh, Shinji and Shakado, Satoshi and Sugimoto, Rie and Morita, Yusuke and Kuwashiro, Takuya and Endo, Mizuki and Iwao, Masao and Motoyoshi, Yasuhide and Nakano, Masahito and Shimose, Shigeo and Takahashi, Hirokazu and Yatsuhashi, Hiroshi and Hirai, Fumihito and Yoshizumi, Tomoharu and Miyaaki, Hisamitsu and Kawaguchi, Takumi and Ido, Akio and Harada, Masaru},
  title = {Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.17024}
}
Kostenlos starten →